The p53 tumor suppressor is a tetrameric transcription factor that is posttranslational modified at -1 8 different sites by phosphorylation, acetylation, or sumoylation in response to various cellular stress conditions. Specific posttranslational modifications, or groups of modifications, that result from the activation of different stress-induced signaling pathways are thought to modulate p53 activity to regulate cell fate by inducing cell cycle arrest, apoptosis, or cellular senescence. Here we review the posttranslational modifications to p53 and the pathways that produce them in response to both genotoxic and non-genotoxic stresses.
carboxyl-terminal tetramerization and regulatory domain (Fig. 1) . In the N-terminal domain, residues 1-42 are required for transactivation activity and interact with the transcription factors TFIID, TFIIH, several TAFs, the histone acetyltransferases CBP/p300 and possibly PCAF, as well as the MDM2 ubiquitin ligase. Residues 17-28 form an amphipathic helix that interacts directly with a hydrophobic cleft in the N-terminal domain of MDM2 [8] , while residues 11-26 are reported to function as a secondary nuclear export signal [9] . Residues 63-97 comprise a proline-rich SH3 domain required for interaction with the Sin3 corepressor [lo] and other proteins required for the induction of apoptosis. While residues 1-31 and 80-101 are highly conserved, especially among mammals, residues 32-79 are poorly conserved in sequence even among mammals.
The majority of tumor-derived p53 mutations affect the central domain and block or alter sequence-specific DNA binding either by destabilizing the domain or through changes to residues that directly contact DNA. The three-dimensional structure of the DNA binding domain bound to DNA was determined by X-ray crystallography [l 11. The consensus DNA binding site is composed of two 10 bp segments (RRRCWWGYYY) separated by 0-13 bp. The carboxyterminal region contains the nuclear localization signal (3 12-324), a tetramerization domain (323-356) and a basic segment that binds certain DNA structures, including short single strands, four-way junctions, and insertions/deletions in a sequence independent manner [ 121. Only tetrameric p53 appears to be active as a transcription factor.
Posttranslational modifications to p53.
p53 activity is thought to be regulated largely through numerous posttranslational modifications that occur mainly in the N-and C-terminal regions (Fig. 1) . Using monoclonal or affinity-purified polyclonal antibodies produced by several laboratories and companies that recognize specific, modified sites in human or mouse p53, increased phosphorylation at most of the 15 known phosphorylation sites has been demonstrated in response to the treatment of cells with DNA damage-inducing agents in Western immunoblot experiments (reviewed in [ 131) .
Seven serines and two threonines in the N-terminal domain of human p53, specifically Ser6, 9, 15, 20, 33, 37, 46 and Thrl8 and 81 , are phosphorylated in response to exposing cells to ionizing radiation or W light. Recently, Thr55 was found to be phosphorylated in unstressed cells [ 141 and dephosphorylated after DNA damage (X. Liu, personal communication). Thus, all Nterminal serines and threonines in the first 89 residues of human p53 may be phosphorylated or dephosphorylated in response to one or more stress conditions. In the C-terminal regulatory domain, Ser3 15 and Ser392 are phosphorylated, Lys320,373 and 382 are acetylated, and Lys386 is sumoylated in response to DNA damage. Ser376 and 378 were reported to be constitutively phosphorylated in unstressed cells, while Ser376 was dephosphorylated in response to ionizing radiation [l5]. Thr155 and Thrl50 or Ser149 in the central site-specific DNA binding domain recently were reported to be phosphorylated by the COP9 signalosome (CSN)-associated kinase [16] ; so far, these are the only sites in the central domain that have been reported to be posttranslationally modified.
Regulation of p53 activity.
The biochemical mechanisms that regulate p53 activity are complex and incompletely understood, but it is widely believed that activation of p53 as a transcription factor involves two stages.
A. p53 stabilization.
First, in response to stress-activated signaling pathways, p53 is stabilized and accumulates in the nucleus. In unstressed cells, p53 protein is maintained at low steady-state levels and has a short half-live due to rapid, ubiquitin-dependent degradation through the 26s proteosome. Ubiquitin is a 76 amino acid polypeptide that is transferred to lysine residues in proteins by ubiquitin ligases; multiple ubiquitination targets the protein to the26S proteosome complex where it is degraded. At least three cellular systems that target p53 for ubiquitination have been described. In the Go phase of the cell cycle, the Jun N-terminal kinase (JNK) binds p53 and targets it for ubiquitination [17] . Activation of JNK in response to DNA damage allows JNK to phosphorylate p53 on Thr8 1, enhancing its transactivation potential and releasing JNK from p53. The COP9 signalosome (SSN) recently was shown to bind p53, phosphorylate it on Thr155 and nearby residues, and promote p53 degradation by targeting it for ubiquitination [16] .
Inhibition of the CSN-associated kinase activity or mutation of Thr155 to valine resulted in increased p53 stability and its accumulation. The CSN kinase is thought to be constitutively active; thus, CSN is believe to contribute to the normal turnover of p53 in cells, but it is not known if modulation of the CSN kinase activity in response to stress contributes to p53 stability.
In dividing cells, the primary system that ubiquitinates p53 is the MDM2 E3 ubiquitin ligase. This activity of MDM2 is vital as shown by the rescue of Mdm2 knock-out mice fi-om embryonic lethality by deletion of p53. Interestingly, loss of MdmX expression also results in embryonic lethality that is rescued by deletion of p53 [18] . MdmX is a structurally related protein that interacts with Mdm2 and blocks p53 degradation. A cleft in the N-terminal domain of MDM2 (amino acids 25-109) binds to an amphipathic helix (amino acids 17-29) in the transactivation domain at the N-terminus of p53 [8] , and binding is required for subsequent ubiquitination at multiple C-terminal p53 lysines. p53 is phosphorylated at several N-terminal sites that reside in or near the MDM2 binding site by kinases activated through several stress response pathways; this led to the hypothesis that phosphorylation might stabilize p53 by preventing its interaction with MDM2 [19] . Initially it was proposed that phosphorylation of Serl5 and 37 in response to DNA damage induced a conformational change in p53 that prevented its interaction with MDM2, thus inhibiting p53 ubiquitination [ 191. Subsequently, phosphorylation of Thrl8 and Sed0 were reported to negatively regulated the interaction of p53 with MDM2 [20-231. Both Thrl8 and Ser20 lie within the p53 N-terminal amphipathic helix that directly interacts with the N-terminus of MDM2. Thrl8 makes several hydrogen bonds with neighboring residues that stabilize the helix and that would be disrupted by phosphorylation.
Consistent with the structural data, phosphorylation of Thrl8, but not phosphorylation of Serl5, Ser20, or Ser37, was found to interfere directly with the interaction of an N-terminal p53 peptide with the N-terminal domain of MDM2 [22, 24] . Nevertheless, changing Serl5 to alanine was shown to significantly decrease the ability of p53 to activate transcription and induce apoptosis in both human [19,2'5] and mouse [26] systems, and changing Sed0 to alanine in human p53 abrogated stabilization in response to DNA damage [20] . Taken together, these results suggest that phosphorylation of p53 Serl5 and Ser20 may indirectly affect complex formation with Mdm2. One mechanism that would be consistent with the present results is increased competition for binding to the N-terminus of phosphorylated p53 by other factors. For example, CBP/p300 interacts with the N-terminus of p53, and binding is dramatically enhanced by phosphorylation of Serl5 [27] . Consistent with this finding, changing Ser6, Ser9, Serl5, or Thrl8 (but not more distal serines) to alanine reduced acetylation of Lys382 [28] . Surprisingly, however, changing murine Ser23, the equivalent of human Ser20, to alanine had no measurable affect on transactivation, apoptosis, and Mdm2 binding in mouse ES cells, fibroblasts, or thymocytes [29] . Thus, it spite of the high degree of sequence conservation between human and mouse p53 in this region, the two species appear to regulate p53 stabilization and MDM2 contains numerous basic residues, and subsequently it was found to bind single-stranded DNA and RNA, as well as several DNA structures. An alternative model to explain latency was proposed by Anderson et a1 [37] , who showed that the sequence-specific DNA binding of p53 was inhibited by long DNAs but not by short oligonucleotides (Fig. 2, top) . These results suggested that strong non-sequence-specific binding by the C-terminal domain of tetrameric p53 prevented sequence-specific binding. Furthermore, relief of inhibition of sequence-specific DNA binding through removal of the C-terminus only occurred in the presence of long DNA molecules. The interference model recently received indirect support fiom NMR-based structural studies on a dimeric derivative of p53 and its C-terminal truncated form [38] . No significant differences in the structure of the central DNA binding domain were observed between the two foims, suggesting that increased DNA binding did not result fiom an allosteric conformational change in p53 structure. However, the concept of a latent DNA binding form of p53 recently was challenged by the finding that unmodified p53 binds well to long DNAs containing consensus recognition sites [39] . Indeed, p53 was reported to be constitutively bound to chromatin at some recognitions sites in vivo, including sites in the CDKNlA 021, WAFI, CIPI) , and MDM2 promoters [40] . Furthermore, genotoxic stress caused only a small increase in the amount of p53 bound to chromatin at these sites.
If DNNchromatin binding is not the rate limiting step for activation of p53, then what might this step be? Although direct attempts to demonstrate a role for p53 acetylation in transcriptional activation in vivo have been unsuccessful [4 11, the importance of histone acetyltransferases (HATS) for p53 transcriptional activity was demonstrated by overexpression of the histone deacetylases HDAC-1, -2, or -3, or hSir2, which deacetylate p53 and inhibit the transcription of p53-target genes [42-461. These and other recent results suggest an alternative model for p53 mediated transcriptional activation in which p53 serves to target HATS to the promoters of p53 activated target genes (Fig. 2, bottom) . Likewise, the targeting of HDACs by p53 to p53 repressed genes has been suggested as a mechanism of p53-mediate gene repression [47] . The mechanisms by which HATS (and HDACs) associate with p53 are not completely understood. As noted above, we previously proposed that DNA damage induced N-terminal phosphorylations promote the association of p300/CBP with p53 [36] . However, other targeting mechanisms may exist. Recently it was suggested that acetylated residues in the p53 C-teiminus may serve to recruit co-activators [48] .
A role for p53 in targeting the co-activator p300 to chromatin is consistent with recent in vitro transcription studies by Espinosa and Emerson [39] . They found that a plasmid containing the CDKNlA (p21) promoter, which contains two p53 binding sites located 2.3 and 1.5 kb proximal of the transcription start site, was not transcribed efficiently when assembled into, chromatin. Transcription was strongly enhanced, however, by addition of both p53 and p300 but not by either factor alone. Importantly, unacetylated p53 bound efficiently to the plasmid DNA and with even higher affinity to the nucleosomal template, but not to a 25 base pair oligonucleotide containing the 5' p21 promoter consensus site. Transcriptional activation required the C-terminus of p53 but not acetylation of C-terminal sites. Furthermore, p53 was shown to induce acetylation of nucleosomal histones preferentially in the promoter region of the chromosomal template, consistent with the model depicted in Fig. 2 (bottom) . The authors [39] suggested that binding of p53 to consensus sites in long DNA might be facilitated by the ability of long DNA, but not short oligonucleotides, to form non-B-DNA structures [49] DNAse I chromatin hypersensitivity is a hallmark of promoter regions of actively transcribed genes, where as the promoter regions of inactive genes usually are insensitive to DNAse I.
IV. Activation of p53 by genotoxic stresses.
Mammalian cells appear to have at least two largely independent signaling pathways for activating p53 in response to genotoxic stress; one is activated by the presence of DNA doublestrand breaks, the other in response to bulky lesions such as pyrimidine dimers and base adducts.
A. Ionizing radiation.
Treatment of cells with ionizing radiation or several radiomimetics (e.g. neocarzinostatin, bleomycin) activates several kinases that phosphorylate p53 at multiple sites (Fig. 3) . Although the molecular mechanism(s) by which DNA strand breaks are recognized are still obscure, key among the kinases activated in response to DNA breaks is ATM, a protein kinase member of the phosphatidylinositol-3-kinase kinase family encoded by the gene responsible for the human genetic disorder ataxia telangiectasia (A-T). ATM directly phosphorylates p53 at Serl5 and activates several other protein kinases that phosphorylate the N-terminal transactivation domain including Chkl and Chk2, which phosphorylate p53 at Sed0 and perhaps other residues (Fig. 1 ).
ATM appears to activate other, unidentified protein kinases that directly phosphorylated Ser9 and Ser46 [28] . Protein kinases that directly phosphorylate Ser6, Ser33, Ser37, and Ser3 15 appear to be activated in response to DNA double-strand breaks by ATM-independent pathways, although inactivation of possible site-specific phosphatases for these residues in response to DNA strand breaks cannot be ruled out. Induction of phosphorylation through substrate modification also is possible. Casein kinase 1 (CK1) phosphorylates sites two residues distal to a previously phosphorylated serine or threonine. In vitro p53 previously phosphorylated at Ser6 and Serl5 is phosphorylated by CKl at Ser9 or Thrl8, respectively [22, 52] . Thus, CK1, or a similar activity, may provide a mechanism for phosphorylation site signal amplification, at least in some cells. Several kinases, including CAK (Ser33), CDK (Ser3 15), PKA, and PKC (Ser376, Ser378), that are capable of phosphorylating p53 in vitro have been identified (Fig. l) , but if and how these might be activated in response to DNA strand breaks is unknown (reviewed in [13] ).
DNA-PK, another PI-3K family member that phosphorylates p53 at both Serl5 and Ser37 in vitro, is directly activated by DNA strand breaks through targeting to DNA ends by its Ku subunit, but its role in vivo remains uncertain. A recent study reported that p53 is found in a complex that contains nucleotide analogue-modified DNA and activated DNA-PK [53] . 
B. UV light.
A second DNA damage response pathway is activated in response to bulky lesions, such as the pyrimidine dimers caused by W -C (Fig. 3) . As for IR, the molecular mechanism(s) responsible for sensing W damaged DNA are not known, although the pathway is though to involve sensing a block to transcriptional elongation [56] and activation of a third PI-3 kinase family member, ATR (A-T and Rad3-related) [57] . Recently, it was reported that ATR exhibits preferential binding to W-damaged DNA; thus, under some circumstance, it may act directly as a sensor of W damage [58] . In vitro ATR phosphorylates p53 on Serl5 and Ser37. UV-C also induces p53 phosphorylation on Ser6, 9, 20, 33, 46, 315, 392 , and on Thrl8 and 81 (Fig. 3) 
C. Carboxy-terminal DNA damage-induced p53 modifications.
As noted above, two C-terminal PKC sites, Ser376 and 378, were reported to be constitutively phosphorylated in the absence of DNA damage [ 151. Thr55 also may be constitutively phosphorylated and then dephosphorylated in response to DNA damage.
Treatment of MFC7 cells with IR led to the ATM-dependent dephosphorylation of Ser376 and to the association of p53 with a 14-3-3 protein, which increased its in vitro affinity for sequencespecific DNA. A confounding observation is the fact that p53 fi-om unstressed cells is recognized by the monoclonal antibody PAb421, which recognizes an epitope including Lys372 to Lys382, but recognition is inhibited by phosphorylation of Ser376 or Ser378 (and acetylation of Lys382).
Recently H7, an inhibitor of PKC, was reported to prevent p53 ubiquitination and to stiinulate p53 accumulation in cells without inducing its activation, suggesting that the constitutive phosphorylation of p53 at Ser376 and/or Ser378 contributes to its degradation [66] . The function of W-mediated phosphorylation of Ser392 is not clear, as previously Ser392 was shown not to be required for the suppression of cell growth or the activation of transcription [67] . In vitro, phosphorylation of Ser392 stimulated formation of p53 tetramers, while phosphorylation of Ser3 15 reversed this effect [68] ; however, these effects are seen at low p53 concentrations and may have been masked in cells overexpressing exogenous p53.
The acetylation of several C-terminal p53 lysines is stimulated by several forms of stress including the genotoxic damage caused by both W and IR [36, 69] . These residues including Lys320, which is acetylated by PCAF iiz vitro, and Lys373 and Lys382, which can be acetylated by p300/CBP. Prior to the discovery of DNA damage-mediated p53 acetylation, CBP/p300 and PCAF were shown to be co-activators of p53-mediated transcription. As noted above, C-terminal acetylation is promoted by the phosphorylation of N-terminal sites, especially Serl5, but acetylation at Lys382 also was enhanced by phosphorylation at nearby residues, including Ser6, Ser9, and Thrl8 [28] . However, in A549 cells acetylation was not induced equivalently by IR and U V . Acetylation, especially of Lys320, was much more strongly induced by W than IR.
Potential roles for p53 acetylation include contributions to p53 stability through interference with C-terminal ubiquitination and the modulation of p53's interactions with other proteins and DNA.
Possible roles for p53 in targeting HATS and HDACs to chromatin are discussed above and illustrated in Fig. 2. 
D. Other genotoxic agents.
Because of their convenience, ionizing radiation and W light commonly are used in the laboratory to produce two different forms to genotoxic damage, i.e. DNA double-strand breaks and pyrimidine dimers. Many other environmental, physiological, and therapeutic agents cause genotoxic damage that activate p53 through one or more signaling pathways. These include anticancer drugs such as adriamycin, topoisomerase inhibitors such as camptothecin, etoposide, and quercetin, DNA synthesis and transcription inhibitors including aphidicolin, actinomycin D and 5,6-dichloro-1 -beta-D-ribofuranosylbenzimidazole (DRB), DNA cross-linking agents such as cisplatinin and mitomycin Cy and environmental chemicals including arsnite, cadmium, and chromate. Each of the above agents have been shown to induces p53 accumulation and its phosphorylation on Serl5 except DRB, which interferes with phosphorylation of the CTD domain of RNA polymerase I1 rather than with elongation [70] . For most of these agents, however, modifications to p53 at other sites have not been investigated.
V. Activation of p53 by non-genotoxic stresses.
p53 activation occurs in response to several physiological processes that are not associated with frank DNA damage, including hypoxia, nucleotide deprivation, microtubule idubitors, oncogene activation and senescence potentiated by telomere erosion. Some of these processes may be mimicked by pharmacological agents which may or may not induce identical responses.
A. Hypoxia.
Tumor hypoxia occurs in most solid tumors from abnormal vasculature development; hypoxia also is an important pathophysiological feature of ischemic disorders. Hypoxia and several hypoxia mimetics have been shown to induce p53 accumulation as a result of the downregulation of MDM2 [71] with concomitant phosphorylation of Serl5, but not acetylation of Lys382 [72] (Fig. 3) . However, in contrast to IR, hypoxia treatment failed to induce the transcription of downstream effector mRNAs including GADD45, Bax, and p21 [72] . Hypoxia does not induce detectable DNA damage, and, in contrast to DNA damage-inducing agents, primarily caused an association of p53 with mSin3A rather than p300. Consistent with this finding, p53-mediated transrepression was induced. In hypoxia treated human papillomavirus HPV-16 transformed cells, p53 was resistant to E6-mediated degradation, and its association with E6AP was reduced [71] . Interestingly, a recent study has shown that inhibition of ATR kinase activity reduced the hypoxia-induced phosphorylation of p53 protein on Serl5 as well as p53 protein accumulation [73] . These data suggest that hypoxia could select for the loss of ATRdependent checkpoint controls, thus promoting cell transformation.
B. Ribonucleotide depletion.
Studies by L i k e et al. [74] showed that p53 is activated in normal human fibroblasts by the N-phosphoacetyl-L-aspartate-induced (PALA) depletion of ribonucleotides in the absence of detectable DNA damage. In contrast to the GI arrest induced by DNA damage, that induced by PALA was readily reversible. PALA treatment induced a pattern of gene expression that was distinct fi-om that induced by IR. Some of these, such as MDGI, a mammary-derived growth inhibitor gene, were induced independent of p53 while for others, such as TSG6, a tumor necrosis factor stimulated gene, induction was p53 dependent [75] . The modification status of p53 after PALA treatment has not been address.
C. Microtubule disruption.
Activation of p53 also occurs in response to factors such as colcemid, nocodazole, and taxol that deregulate cell adhesion or microtubule architecture and dynamics. Tax01 (Paclitaxel), which inhibits microtubule depolymerization, is one of the newer chemotherapy drugs commonly is used to treat ovarian, breast, and head and neck cancers. After nocodazole treatment, which depolymerizes microtubules, quiescent human fibroblasts accumulated transcriptionally active p53 and arrested in GI with a 4 N DNA content [76] . Activation of p53 after colcemid treatment was accompanied by a moderate increase in phosphorylation at Serl5 and correlated with activation of Erkl/2 MAP kinases and the development of focal adhesions rather than'disi-uption of the microtubule system [77] . Curiously, murine fibroblasts did not undergo the same response. Taxol and vincristine, but not nocodazole, were found to induced multi-site phosphorylation of p53 in several tumor-derived human cell lines, including and RKO cells, and the pattern of p53 phosphorylation was distinct from that observed after DNA damage [78] . Nevertheless, both nocodozole and taxol increased phosphorylation at Serl5 (Fig. 3) . Interestingly, microtubule inhibitor-induced p53 stabilization and Serl5 phosphorylation did not occur in ATM-deficient fibroblasts nor in normal human dermal fibroblasts. Studies with ectopically expressed p53 phosphorylation site mutants indicated that several p53 aminoterminal residues, including Serl5 and Thrl8, were required for the taxol-mediated phosphorylation of p53 [78] . In contrast, Damia et al. [79] reported that taxol induced p53 phosphorylation at Sed0 but not at Serl5 in HCT-116 cells. Phosphorylation at Sed0 was accompanied by increased Chk2 activity and was not inhibited in A-T cells lines nor by wortmannin treatment. Thus, the signaling pathways that impinge on p53 after hypoxia, ribonucleotide depletion or microtubule disruption, while still not well defined, appear distinct from those induced by genotoxic stresses.
D. Oncogene activation.
Oncogenes, such as Ras, c-Myc or El a, when activated or overexpressed, stabilize and activate p53, and depending on the cell type, induce senescence (Ras) or apoptosis (c-Myc or terminal sites, nor was it acetylated at Lys382 (Fig. 3) . Interestingly, a similar induction of permanent cell cycle arrest resembling cellular senescence was produced in murine fibroblasts engineered to express the MAP kinase Mekl [84] . The induction of senescence by Ras required wildtype p53 and ARF, but p53 was not required to maintain the senescent state. These data indicate that other signals may influence the outcome of p53 activation, likely by changing its association with various coactivators; however, whether this leads to the expression of different p53 target genes remains to be determined.
E. Replicative senescence.
Replicative senescence in human fibroblasts correlates with activation of p53-dependent transcription and was shown to be associated with increased phosphorylation at Serl5, Thrl8, and probably Ser376, and decreased phosphorylation at Ser392 [85] (Fig. 3) . It was inferred from the finding that no change occurred in staining with the DO-1 monoclonal antibody, the epitope for which includes Ser20, that phosphorylation on Sed0 was not induced. These results, in conjunction with findings showing that changes in p53 phosphorylation are abrogated in cells which have been immortalized by overexpression of telomerase, indicate that the above modifications may be the product of telomere erosion. Shorten or disrupted telomere structures may signal to p53 via pathways partially shared with DNA damage responses.
VII. Conclusions.
Multiple, distinct signal transduction pathways clearly activate and modulate p53-dependent transcription in response to both genotoxic and noli-genotoxic stresses. Although key protein kinases that are likely to phosphorylate p53 in response to DNA damage have been identified, the identities of kinases that phosphorylate several important sites are still unknown.
Furthermore, several sites may be phosphorylated by more than one protein hnase. This complexity is augmented further by the facts that signaling pathway activation may be cell-type and cell-cycle dependent and that many signaling initiation events activate more than one pathway. 
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Although CBP/p300 and PCAF acetylate lysines at the C-terminus of p53, mutation of these sites failed to demonstrate a strong effect on p53-mediated transcription [38] . Instead, recruitment of HATS and HDACs to promoter sites may alter chromatin structure in the vicinity of p53 promoters, suggesting that activation of p53-mediated transcription may result from the action of these coactivators and repressors on the modification state and structure of chromatin in the vicinity of p53 promoters [39] . Anderson and Appella Figure 3 
